Federal funding of $383.4 million enhances behavioral health services nationwide, focusing on treatment, prevention, and crisis response.
Axogen acquires BioCircuit Technologies in a $200M deal to expand its peripheral nerve repair offerings and market position.
New treatment improves survival in first-line small cell lung cancer with a combination of tarlatamab and durvalumab, showing a significant clinical benefit.
Hospitals face steep CAR T-cell therapy costs, from drug pricing to staffing and safety protocols, straining smaller clinics and outpatient programs.
tozorakimab COPD therapy shows significant reduction of inflammation by targeting multiple pathways, offering new hope beyond eosinophil‑focused treatments.
Eosinophil guided steroid reduction in COPD cuts ICS doses without raising severe flare‑ups, according to the COPERNICOS trial at the 2026 ERS…
The FDA approves camizestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Learn about this new treatment option and its clinica
Adjunct antipsychotics are emerging as a promising option for treating depression when antidepressants fall short, offering new hope for patients.
Cancer telehealth is bridging the vast distance barrier for Mountain West patients, offering remote specialist access and reducing travel hardships.
Evolocumab reduces heart attack risk by 20% in high-risk patients with atherosclerosis or diabetes, lowering mortality rates effectively.